Wuxi Biologics Placement: Almost All of the past Deals Have Done Well, Would Bid near the Bottom End
Wuxi Biologics Holdings is looking to raise upto US$672m by selling 4.2% of Wuxi Biologics (Cayman) Inc (2269 HK). This will be seventh placement...
491 Views
HK Connect Flows: Close Meituan/Elong Trade with a 14.5% Profit
In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...
341 Views
HK Connect Flows: USD 729 Million Inflows into Meituan Since Inclusion
In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...
401 Views
WuXi Biologics Placement: An Attractive Opportunity
Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research...
391 Views
Wuxi Biologics Placement: A Larger Deal but Performance Track Record Weighs
Wuxi Biologics is looking to raise upto US$770m by selling 35 million primary shares and selling 35million shares held by its main shareholder Wuxi...
522 Views